Details of the Drug Combination

General Information of Drug Combination (ID: DCDV78F)

• Drug Combination Name: Bedaquiline + Moxifloxacin
• Indication: Tuberculosis, Pulmonary; Status: Phase 2 [1]
• Component Drugs:
  Bedaquiline (DM3906J): Small molecular drug
  Moxifloxacin (DMU8V4S): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Bedaquiline

Disease Entry	ICD 11	Status	REF
Drug-resistant tuberculosis	N.A.	Approved	[2]
Multi-drug resistant tuberculosis	MG52.00	Approved	[3]
Pulmonary tuberculosis	1B10.Z	Approved	[2]

Bedaquiline Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Mycobacterium Proton pump (MycB Prop)	TT19K0L	A0A1Q4HQH4_9MYCO	Modulator	[6]

Bedaquiline Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[7]

Indication(s) of Moxifloxacin

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[4]
Mycoplasma pneumoniae pneumonia	N.A.	Approved	[5]
Peritonitis	N.A.	Approved	[5]
Pneumonic plague	N.A.	Approved	[5]
Septicemic plague	N.A.	Approved	[5]
Staphylococcal pneumonia	N.A.	Approved	[5]
Staphylococcus aureus infection	N.A.	Approved	[5]
Streptococcal pneumonia	N.A.	Approved	[5]
Tuberculosis	1B10-1B14	Approved	[5]
Pneumonia caused by chlamydia	N.A.	Investigative	[5]
Pneumonia due to Klebsiella pneumoniae	CA40.03	Investigative	[5]

Moxifloxacin Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Bacterial DNA gyrase (Bact gyrase)	TTN6J5F	GYRA_STAAU; GYRB_STAAU	Modulator	[8]
Staphylococcus Topoisomerase IV (Stap-coc parC)	TTIXTO3	PARC_STAAS	Modulator	[8]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Pulmonary Tuberculosis	DCVMZGP	N. A.	Phase 2	[9]

References

• [1] ClinicalTrials.gov (NCT05926466) BTZ-043 Dose Evaluation in Combination and Selection
• [2] Bedaquiline FDA Label
• [3] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [4] Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
• [5] Moxifloxacin FDA Label
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [7] Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014 May;42(5):863-6.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [9] ClinicalTrials.gov (NCT06114628) Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB